Introduction
============

Stroke is a major cause of mortality and disability in adults, and the second leading cause of death worldwide with an annual incidence of 250 to 400 in 100,000 people. This leads to a huge social and economic burden ([@b1-ijsc_07_63]). Currently very few therapeutic options are available. The currently available therapies of acute stroke target rapid vessel recanalization and neuroprotection, since without restoration of cerebral blood flow, tissue residing in the penumbral region progresses to cellular death which ultimately expands the core lesion. Recombinant tissue plasminogen activator (tPA) is the only pharmacological treatment approved for treatment of acute ischemic stroke. The tPA therapy restores the brain function when performed within the time window of 4 to 5 hours after acute ischemic stroke, which limits its use to a small minority (2% to 4%) of patients ([@b2-ijsc_07_63]). Moreover, tPA prevents disability in only six patients per 1000 ischemic strokes, and does not reduce the mortality rate ([@b3-ijsc_07_63]).

An alternative potential new approach in the treatment of ischemic stroke is cell-based therapy. Preclinical rodent models of ischemic stroke and clinical trials using stem cells or adult and fetal progenitor cells have shown a therapeutic promise. Stem cells are undifferentiated cells that have the capacity to proliferate and differentiate into mature specialized cells ([@b4-ijsc_07_63]). However, the effects of these treatments are not yet fully understood and there is a lack of firm evidence on the efficacy and safety of stem cell therapy for those patients due to the absence of sufficiently powered randomized controlled trials. Therefore, we performed a meta-analysis of available single-arm studies using stem cell-based therapy in patients with stroke.

Methods
=======

Search strategy and study selection
-----------------------------------

This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (<http://www.prisma-statement.org/>). A systematic search and critical review of the literature published from its inception through July 2014 was performed. We searched MEDLINE, EMBASE, and the Cochrane database for studies of stem cell therapy in patients with stroke.

An inclusion criterion was stem cell therapies for stroke patients. We cannot restricted any type of stroke either acute or chronic patients. The excluded studies met the following criteria: ([@b1-ijsc_07_63]) Individual case reports ([@b2-ijsc_07_63]) irretrievable or unclear data ([@b3-ijsc_07_63]) duplicate reports. Article selection process was conducted by two authors independently with standard methods.

Data extraction
---------------

Two investigators independently screened all titles and abstracts to identify studies that met the inclusion criteria and extracted relevant data, with divergences resolved by consensus. We included single-arm studies as well as experimental arm of nonrandomized or randomized controlled trials in patients with stroke. The following data were extracted: country of origin, year of publication, numbers of patients who injected stem cells, follow-up period, stem cell type, injected cell dose, route of administration, and disease elapsed time which was classified into either "acute" within 30 days after onset of stroke or "chronic" 30 days or more after onset of stroke. The outcome measures included changes of National Institutes of Health Stroke Scale (NIHSS) and modified Bathel index (BI) scores from the baseline to primary endpoints and the event rate of modified Rankin Score (mRS)≤2 at primary endpoints for evaluating the efficacy and count the frequencies of adverse events for appreciating the safety for stem cell therapy. All data were extracted accordance with the criteria based on the Cochrane Handbook for Systematic Reviews of Interventions ([@b5-ijsc_07_63]).

Quality assessment
------------------

Quality assessment of single arm studies and experimental study arms was evaluated using the Newcastle Ottawa Scale (NOS) ([@b6-ijsc_07_63]). This scale allocates a maximum of 9 stars for quality of selection (up to 4 points), comparability (up to 2 points) and outcome (up to 3 points) of study participants. Overall study quality was defined arbitrarily as poor (score, 0∼3), fair (score, 4∼6) or good (score, 7∼9). Quality assessments were conducted independently by two authors. Disagreements were resolved by discussion between the two authors.

Statistical analyses
--------------------

We performed random effects model meta-analyses to assess net changes in the same outcome variables. Existence of heterogeneity among effect sizes of individual studies was assessed using the *I^2^* index and Q statistic. Heterogeneity was analyzed with the *I^2^* statistic, and heterogeneity was defined as low (25% to 50%), moderate (50% to 75%), or high (\>75%) ([@b7-ijsc_07_63]). Preplanned subgroup analyses were conducted based on injected cell type, follow-up periods, route of administration, disease elapsed time, and study sample size. Subgroups divided into acute vs. chronic stroke patients, Bone marrow derived mononuclear cells (BM-MNC) vs. other than BM-MNC, injected stem cell through intra-artery vs. other than routes, 6 months vs. 12 month or more follow-ups, and less than 10 vs. 10 or more sample size. We conducted meta-regression analysis to determine factors related to decrease in NIHSS after stem cell therapy. Data analyses were performed using Comprehensive Meta-analysis version 2.2. (Biostat Inc., Englewood, NJ).

Results
=======

Search results
--------------

The initial search identified 1482 articles, of which 1392 articles excluded in the first screening. Ninety potentially relevant articles examined in more detail. Of these, 76 were exclude experimental studies, review, editorials, or comment, secondary publication, case reports, or did not reported outcome data. Fourteen of the 90 potentially relevant articles were eligible for meta-analysis ([Fig. 1](#f1-ijsc_07_63){ref-type="fig"}) ([@b8-ijsc_07_63]--[@b20-ijsc_07_63]).

Characteristics of the included studies
---------------------------------------

Characteristics of 14 studies are described in [Table 1](#t1-ijsc_07_63){ref-type="table"}. All studies were published from 2005 to 2013. Study samples size ranged from 5 to 20 patients and follow-up duration from 6 to 60 months. The type of stem cell varied, being either CD34+ cells or bone marrow mononuclear cells, Bone marrow derived mesenchymal stem cell, fetus stem cell, and fetal porcine cell. Stem cells were injected through parenchyma, intrathecal, intra-arterial, or intravenous with the range from 5 to 300 million cell dose. In addition, the overall quality scores of the included single arm studies and experimental study arms were presented in [Table 1](#t1-ijsc_07_63){ref-type="table"}. Two of 14 studies were assessed the study quality as good, 9 were fair, and 3 were poor.

Main findings
-------------

Ten out of 14 included studies have evaluated the efficacy of stem cell therapy using changing score in NIHSS ([@b8-ijsc_07_63]--[@b11-ijsc_07_63], [@b13-ijsc_07_63]--[@b16-ijsc_07_63], [@b18-ijsc_07_63], [@b20-ijsc_07_63]). The pooled mean difference in NIHSS from baseline to follow-up points was 5.7 points (95%CI: −8.2 to −3.2, *I^2^*=91.5%) decreased. Six studies have reported BI score to assess the efficacy of the treatment ([@b10-ijsc_07_63], [@b14-ijsc_07_63], [@b18-ijsc_07_63]--[@b21-ijsc_07_63]). The pooled mean difference in BI score was increased by 31.5 points (95%CI: 35.6∼14.9, *I^2^*=52.7%). Seven studies have counted the number of patients who have achieved 2 or less in mRS ([@b8-ijsc_07_63]--[@b11-ijsc_07_63], [@b14-ijsc_07_63], [@b16-ijsc_07_63], [@b17-ijsc_07_63], [@b20-ijsc_07_63]). The pooled incidence rate to achieve on mRS≤2 was 40% (95% CI: 30%∼51%, *I^2^*=35.4%) at follow-up points ([Fig. 2](#f2-ijsc_07_63){ref-type="fig"}).

Ten out of 14 studies have reported incidence of adverse events such as death, seizure, and infection after injection of stem cell ([@b8-ijsc_07_63]--[@b17-ijsc_07_63]). The pooled incidence of occurring infection, seizure, and death after cell transplant were 15% (95% CI: 8∼23%), 14% (95% CI: 8∼25%), and 13% (95% CI: 8∼23%) respectively ([Table 2](#t2-ijsc_07_63){ref-type="table"}).

The likelihood of publication bias has been tested by using funnel plot and Egger test for NIHSS. Funnel plot was symmetric shape and the Egger test was not significant (p=0.120), suggesting less susceptibility to publication bias.

Subgroup and meta-regression analyses on the changes in NIHSS
-------------------------------------------------------------

We conducted subgroup analysis to explore the source of heterogeneity in NIHSS with respect to patients' characteristics, injected cell type and dose, route of administration, follow-up period, and sample size of study. Stem cell therapy more effective to acute patients (mean difference=−8.0; 95%CI: −10.7 to −5.7), Bone marrow derived mononuclear cells (mean difference=−7.0 (95%CI: −9.3 to −4.6), higher cell dose (mean difference=−7.1 (95%CI: −10.1 to −4.1), intra-artery injection (mean difference=−8.9; 95%CI: −10.7 to −5.4), short term follow-up studies (mean difference=−8.5; 95%CI: −10.6 to −6.4), and studies of 10 or more sample size (mean difference=−9.0; 95%CI −10.1 to −8.1). However, the results showed that the substantial heterogeneity still remained ([Table 3](#t3-ijsc_07_63){ref-type="table"}).

We conducted meta-regression analysis to determine factors related to decrease in NIHSS after stem cell therapy. The results showed that NIHSS score decrease was related to patients' characteristics, study duration, injected cell type and cell dose, and study sample size in univariate meta-regression. Stem cell therapy was more effective for acute stroke patients than chronic ones. Also the results from short term follow-up (6 months) studies showed more effective than those of long term follow-up (12 or more months) ones, BM-MNC injection was more effective than other stem cell types, intra-artery injection showed more effective than any other administration routes, higher cell dose was more effective than lower ones, and sample size was also related with the efficacy of stem cell therapy ([Table 4](#t4-ijsc_07_63){ref-type="table"}).

Discussion
==========

Approximately16 million first-ever strokes occur each year, leading to nearly 6 million deaths ([@b22-ijsc_07_63]). Nevertheless, very few therapeutic options are available. Stem cell therapy is being investigated for treating stroke with promising results. Several preclinical studies have indicated that there was a structural and/or functional recovery after intracerebral, intra-arterial, and intravenous therapy with different cell types ([@b23-ijsc_07_63], [@b24-ijsc_07_63]). A recent meta-analysis of 117 preclinical stroke studies indicated that for structural structural and functional outcomes were improved ([@b25-ijsc_07_63]). Although preclinical studies for stroke are encouraging, there are still many questions regarding the possible mechanisms of action of the cells and the optimal treatment protocol and the effects of these treatments are not yet fully understood.

In the present single arm meta-analysis, we demonstrated that stem cell therapy was associated with significant improvements in behavioral and functional capacity in patients with stroke. We calculated pooled mean differences between baseline and follow-up points with the universal neuro-physiological assessment tools for stroke. There was significant improvement in motor and behavioral function and functional capacity after stem cell therapy.

However, there are several limitations that should be mentioned. Due to the paucity of randomized controlled trials, this systematic review primarily evaluated cohort studies. With the use of single-arm studies, the observation bias could not be detected in published article, which is a source of heterogeneity. Despite these important limitations, the 5.7 points reduction in NIHSS score represents improvement of stroke symptoms. The change in the scores in the NIHSS was a powerful factor in predicting an excellent outcome after stroke with an increasing of 1 point in a patient's NIHSS score decreases the likelihood of an excellent outcome by 17% ([@b26-ijsc_07_63]). Many stroke trials define favorable outcome as mRS grade ≤ 2 ([@b27-ijsc_07_63], [@b28-ijsc_07_63]). A previous study showed that the mRS cut off score 2 differed greatly between patients with total anterior circulation infarcts and those with lacunar or partial anterior circulation infarcts ([@b29-ijsc_07_63]). The present study showed that 40% (95%CI, 39∼51%) of patients achieved mRS≤2. It reflected that stem cell therapy is effective for stroke patents. The Changes BI scores between baseline and follow-up point was 31.5 points (95% CI, 27.3∼35.6). A study on predicting discharge status at commencement of stroke rehabilitation, BI score difference was about 34 point between initial and discharge, even though the absolute difference in BI score not always represent recovery of the symptoms ([@b30-ijsc_07_63]). Further research might be conducted to confirm the significant score change using this scale to assess the treatment efficacy in stroke patients.

When it comes to incidence adverse events, it should be categorized and evaluated with standardized methods based on common toxicity criteria. Though the limitations still remained, 10 of 14 studies reported Incidence rates of death, seizure, or infection during follow-up ([@b8-ijsc_07_63]--[@b17-ijsc_07_63]). Among the 4 studies reported that there was no adverse event occurred ([@b11-ijsc_07_63], [@b12-ijsc_07_63], [@b14-ijsc_07_63], [@b15-ijsc_07_63]). Seven patients among the 3 studies were died after transplantation due to myocardial infarction, pulmonary embolism, recurrence stroke, and pneumonia ([@b9-ijsc_07_63], [@b10-ijsc_07_63], [@b17-ijsc_07_63]). Six patients of 4 studies reported seizure during follow-up ([@b8-ijsc_07_63], [@b13-ijsc_07_63], [@b16-ijsc_07_63], [@b17-ijsc_07_63]). Most of them considered as a serious adverse event though most of them were successfully treated with antiepileptic drug. Eight patients among the 3 studies reported incidence of infection ([@b8-ijsc_07_63], [@b9-ijsc_07_63], [@b17-ijsc_07_63]). Seven out of 8 patients were infected urinary tract and one was respiratory infection. The pooled incidence rates of death, seizure, and infection were 13% (95%CI, 8∼23%), 15% (95%CI, 8∼25%), and 15% (95%CI, 8∼23%), respectively.

Meta-regression analyses, exploring the source of heterogeneity, indicated that the treatment effects might be associated with patients' characteristics (acute or stroke patients), follow-up period, injected cell type and cell dose, and study sample size. We did not conduct multiple meta-regression analysis because there was not sufficient number of studies was included in the analysis.

Regarding the timing of injection, preclinical studies have shown that cell therapy increased functional recovery after acute, subacute, and chronic stroke ([@b24-ijsc_07_63]). Infusion timing and duration of follow-up period seemed to explain the heterogeneity found in the studies; however, a considerable degree of heterogeneity was still observed among the included trials. This might be due to differences in patients' characteristics, such as different causes and severity at baseline and various treatment protocols, or otherwise unknown biases in those studies.

Conclusion
==========

The published data suggest that stem cell-based therapy for patients with stroke can be judged as effective based on single arm clinical studies. However, clinical benefits of stem cell therapy for patients with stroke need further investigation and reevaluation to test the clinical efficacy.
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###### 

Characteristics of included studies

  Study                      Country   No. of Patient   Follow-up (month)   Cell type                                                     Route of delivery   Cell dose^[\*](#tfn1-ijsc_07_63){ref-type="table-fn"}^ (×100,000)   NOS[^§^](#tfn4-ijsc_07_63){ref-type="table-fn"} score
  -------------------------- --------- ---------------- ------------------- ------------------------------------------------------------- ------------------- ------------------------------------------------------------------- -------------------------------------------------------
  Wang (2013)                China     8                12                  BMC: CD34                                                     Intrathecal         18                                                                  5
  Bhasin (2013)              India     6                6                   MSC[^†^](#tfn2-ijsc_07_63){ref-type="table-fn"}: BM derived   Intravenous         55                                                                  6
  Prasad (2012)              India     11               6                   BM-MNC[^‡^](#tfn3-ijsc_07_63){ref-type="table-fn"}            Intravenous         80                                                                  4
  Bhasin (2012)              India     12               6                   BM-MNC                                                        Intravenous         56                                                                  3
  Moniche (2012)             Spain     10               6                   BM-MNC                                                        Intra-aterial       159                                                                 6
  Friedrich (2012)           Brazil    20               6                   BM-MNC                                                        Intra-aterial       221                                                                 3
  Honmou (2011)              Japan     12               12                  MSC: BM derived                                               Intravenous         110                                                                 3
  Savitz (2011)              USA       10               6                   BM-MNC                                                        Intravenous         10                                                                  5
  Battistella (2011)         Brazil    6                6                   BM-MNC                                                        Intra-aterial       300                                                                 4
  Lee (2010)                 Korea     16               60                  MSC: BM derived                                               Intravenous         5                                                                   7
  Suárez-Monteagudo (2009)   Cuba      5                12                  BM-MNC                                                        Parenchymal         34                                                                  4
  Monteagudo (2009)          Cuba      5                12                  BM-MNC                                                        Parenchymal         35                                                                  4
  Rabinovich (2005)          Russia    10               6                   Fetus stem cell                                               Parenchymal         200                                                                 5
  Savitz (2005)              USA       5                48                  Fetal Porcine Cell                                            Parenchymal         20                                                                  7
  Bang (2005)                Korea     5                12                  MSC: BM derived                                               Intravenous         100                                                                 2

Cell dose: Mean or median dose;

MSC: Mesenchymal stem cell;

BM-MNC: Bone marrow derived mononuclear cells;

NOS score: Quality assessment score using New-Castle Ottawa Scale.

###### 

Pooled incidence of adverse events

  Study                      Death     Seizure   Infection
  -------------------------- --------- --------- -----------
  Friedrich (2012)           2/20      0/20      2/20
  Moniche (2012)             0/10      2/10      3/10
  Battistella (2011)         0/6       2/6       NA
  Honmou (2011)              0/12      0/12      0/12
  Savitz (2011)              1/10      0/10      NA
  LEE (2010)                 5/16      3/16      3/16
  Suárez-Monteagudo (2009)   0/5       0/5       0/5
  Rabinovich (2005)          0/10      0/10      NA
  Savitz (2005)              0/5       1/5       0/5
  Bang (2005)                0/5       NA        0/5
  Pooled incidence           13%       15%       15%
  (95% CI)                   (8∼23%)   (8∼25%)   (8∼23%)

###### 

Subgroup analysis to explore the source of heterogeneity on changes in NIHSS

  Subgroup                    Mean difference (95% CI)   *I^2^*
  --------------------------- -------------------------- --------
  Patients' characteristics                              
    Acute stoke               −8.0 (−10.7 to −5.4)       92
    Chronic stroke            −3.2 (−5.5 to −0.8)        69
  Follow−up period                                       
    6 months                  −8.5 (−10.6 to −6.4)       83
    12 months or more         −2.9 (−4.7 to −1.1)        69
  Cell type                                              
    BMC                       −7.0 (−9.3 to −4.6)        94
    Non BMC                   −3.4 (−7.9 to 1.0)         56
  Route of delivery                                      
    Intra-artery              −8.9 (−12.3 to −5.5)       90
    Other routes              −4.0 (−6.0 to −2.0)        84
  Cell dose                                              
    10^8^                     −7.1 (−10.1 to −4.1)       92
    10^7^                     −3.9 (−6.6 to −1.2)        84
  Study sample size                                      
    Less than 10              −2.0 (−4.0 to −1.9)        0
    More than 10              −9.0 (−10.1 to −8.1)       72

###### 

Meta-regression analysis to assess the relationship between the changes NIHSS and study characteristics

  Study characteristics                                                    Mean difference (95% CI)   p
  ------------------------------------------------------------------------ -------------------------- -------
  Acute stroke (vs. chronic stroke)                                        −3.6 (−5.2 to −1.9)        0.006
  6 month follow-up (vs. 12 mo or more)                                    −3.4 (−5.1 to −1.7)        0.001
  BMC[^\*^](#tfn5-ijsc_07_63){ref-type="table-fn"}(vs. other stem cells)   −5.0 (−7.5 to −2.5)        0.001
  IA[^†^](#tfn6-ijsc_07_63){ref-type="table-fn"} (vs. other routes)        −4.5 (−6.5 to −2.4)        0.007
  10^8^ cell dose (vs. 10^7^ cell dose)                                    −4.7 (−6.9 to −2.4)        0.099
  10 or more sample size                                                   −4.7 (−6.9 to −2.4)        0.005

BMC: Bone Marrow derived stem Cells;

IA: intra-arterial.
